249 related articles for article (PubMed ID: 12205567)
41. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
42. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
43. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
[TBL] [Abstract][Full Text] [Related]
44. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up.
Nachman SA; Navaie-Waliser M; Qureshi MZ
Pediatrics; 1997 Dec; 100(6):E8. PubMed ID: 9382909
[TBL] [Abstract][Full Text] [Related]
45. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
Winchester L; García L; García I; Concepción CB
P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
[TBL] [Abstract][Full Text] [Related]
46. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
48. Health economics and RSV.
Carbonell-Estrany X; Lázaro y de Mercado P
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
[TBL] [Abstract][Full Text] [Related]
49. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
50. RSV outbreak in a paediatric intensive care unit.
Thorburn K; Kerr S; Taylor N; van Saene HK
J Hosp Infect; 2004 Jul; 57(3):194-201. PubMed ID: 15236847
[TBL] [Abstract][Full Text] [Related]
51. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
Committee on Infectious Diseases
Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
[TBL] [Abstract][Full Text] [Related]
52. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
Pin I; Pilenko C; Bost M
Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
[TBL] [Abstract][Full Text] [Related]
53. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
DeVincenzo JP; Aitken J; Harrison L
J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
[TBL] [Abstract][Full Text] [Related]
54. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
[TBL] [Abstract][Full Text] [Related]
55. Rehospitalization for respiratory syncytial virus among premature infants.
Joffe S; Escobar GJ; Black SB; Armstrong MA; Lieu TA
Pediatrics; 1999 Oct; 104(4 Pt 1):894-9. PubMed ID: 10506231
[TBL] [Abstract][Full Text] [Related]
56. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
[TBL] [Abstract][Full Text] [Related]
57. [Outbreak of respiratory syncytial virus at a neonatal intensive care unit in Mexico City].
Murguía-de Sierra T; Casasola-Flores J; Rosales-Urbán S; Nava-Ibarra V; Navarrete-Navarro S
Bol Med Hosp Infant Mex; 1993 Oct; 50(10):709-16. PubMed ID: 8216868
[TBL] [Abstract][Full Text] [Related]
58. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
[TBL] [Abstract][Full Text] [Related]
59. Passive immunisation of preterm infants with palivizumab against RSV infection.
Harkensee C; Brodlie M; Embleton ND; Mckean M
J Infect; 2006 Jan; 52(1):2-8. PubMed ID: 16236360
[TBL] [Abstract][Full Text] [Related]
60. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]